BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $19,291,000 | -26.4% | 411,595 | -4.3% | 0.17% | -21.5% |
Q2 2021 | $26,220,000 | -9.6% | 430,115 | -8.6% | 0.21% | -13.7% |
Q1 2021 | $28,995,000 | -32.8% | 470,700 | -22.4% | 0.25% | -29.1% |
Q4 2020 | $43,147,000 | +77.9% | 606,760 | -6.1% | 0.35% | +54.2% |
Q3 2020 | $24,254,000 | +3.5% | 646,430 | -10.0% | 0.23% | +1.3% |
Q2 2020 | $23,434,000 | +65.7% | 718,629 | +47.4% | 0.22% | +32.5% |
Q1 2020 | $14,142,000 | -18.6% | 487,650 | -1.6% | 0.17% | +9.0% |
Q4 2019 | $17,369,000 | +50.3% | 495,550 | -7.9% | 0.16% | +52.0% |
Q3 2019 | $11,558,000 | +185.7% | 538,330 | +258.9% | 0.10% | +229.0% |
Q2 2019 | $4,046,000 | – | 150,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |